115372 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66748)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bispecific anti‐CD20/19 CAR‐T—zamtocabtagene autoleucel for relapsed/refractory DLBCL—Interim analysis results of DALY‐II‐USA study
    Meeting Abstract

    Ulrickson, M.; Miklos, D. B.; Maziarz, R. T.; Jacobson, C.; Isufi, I.; Ghosh, M.; Perales, M.; Lunning, M.; Hardy, N. M.; Wijatyk, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent BTK‐inhibitor pre‐treated mantle cell lymphoma: Updated results, subgroup analysis from bruin with >3 years follow‐up from start of enrollment
    Meeting Abstract

    Cheah, C. Y.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; Alencar, A. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Durables responses with anti‐CD19 allogeneic CAR T ALLO‐501/501A in phase 1 trials of relapsed/refractory large B‐cell lymphoma (R/R LBCL)
    Meeting Abstract

    Locke, F. L.; Lekakis, L.; Eradat, H.; Munoz, J.; Tees, M.; de Vos, S.; Nath, R.; Stevens, D.; Malik, S.; Popplewell, L.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Baseline SUV and early response, but not MTV, are associated with outcome in relapsed/refractory Hodgkin lymphoma patients treated with nivolumab in the CHECKMATE 205 trial
    Meeting Abstract

    Barrington, S. F.; Fischer, B. M.; Kirkwood, A. A.; Grootendorst, D.; Akyol, A.; Ansell, S. M.; Armand, P.; Schwartz, L. H.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high‐risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Belada, D.; Falchi, L.; Leppä, S.; Vermaat, J. S.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; Nijland, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T‐cell therapy outcome
    Meeting Abstract

    Imber, B. S.; Silverman, E. A.; Leithner, D.; Hubbeling, H.; Shah, G. L.; Fregonese, B.; Sanin, B. W.; Tomas, A. A.; Parascondola, A.; Saldia, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Point‐of‐care anti‐BCMA CAR T‐cell therapy induces encouraging response rates in high‐risk relapsed/refractory multiple myeloma
    Meeting Abstract

    Magen, H.; Fried, S.; Itzhaki, O.; Shem‐Tov, N.; Danylesko, I.; Yerushalmi, R.; Marcus, R.; Shouval, R.; Nevo, L.; Shapira‐Frommer, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Primary overall survival analysis of the phase 3 randomized ZUMA‐7 study of axicabtagene ciloleucel versus standard of care in relapsed/refractory large B‐cell lymphoma
    Meeting Abstract

    Westin, J. R.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A; Ghobadi, A.; Rapoport, A. P.; Sureda, A.; Jacobson, C. A.; Farooq, U.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Nivolumab(N)‐AVD improves progression‐free survival compared to brentuximab vedotin(BV)‐AVD in advanced stage (AS) classic Hodgkin lymphoma (HL): Results of SWOG S1826
    Meeting Abstract

    Herrera, A. F.; LeBlanc, M.; Castellino, S. M.; Li, H.; Rutherford, S. C.; Evens, A. M.; Davison, K.; Punnett, A.; Hodgson, D.; Parsons, S. K.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Improving nursing leadership communication: Fierce conversations™ training
    Journal Article

    McNulty, E. E.
    Clinical Journal of Oncology Nursing (2023)

    Fulltext@MSK | Save